Business
Curis Provides Fourth Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024.
About this update from Curis, Inc.
[{"type":"text","content":"FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"Orphan Drug Designation for PCNSL granted in both US and EU","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"Management to host conference call today at 8:30 a.m. ET","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., March 31, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024.","length":304,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Curis, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Curis, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":207,"url":"https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bs_Ynz1IdxzlIjT8sYZeig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207}},"href":"https://mma.prnewswire.com/media/607886/Curis_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Operational Highlights","length":22,"tagName":"p"},{"type":"text","content":"Emavusertib (IRAK4 Inhibitor)","length":29,"tagName":"p"},{"type":"text","content":"TakeAim Lymphoma","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Curis successfully concluded meetings with both the U.S. Food and Drug Administration (FDA) and the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) on the suitability of using the ongoing TakeAim Lymphoma study (NCT 03328078) to support a potential accelerated approval path in PCNSL.","length":322,"tagName":"p"}]},{"val":[{"type":"text","content":"Curis also announced that emavusertib has been granted Orphan Drug Designation for PCNSL in both the US and Europe.","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Curis provided a data update for 27 patients enrolled in the ongoing TakeAim Lymphoma study in relapsed/refractory (R/R) PCNSL as of J...